Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Glenn X. Liu

Oncology
UW Health
University Of Wisconsin Medical Foundation Inc
600 Highland Ave, 
Madison, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients

Distinguished in WT1-Related Wilms Tumor Syndromes
UW Health
University Of Wisconsin Medical Foundation Inc
600 Highland Ave, 
Madison, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Glenn Liu is an Oncologist in Madison, Wisconsin. Dr. Liu is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, and Orchiectomy. Dr. Liu is currently accepting new patients.

His clinical research consists of co-authoring 95 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in WI
Hospital Affiliations
University Of Wi Hospitals & Clinics Authority
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION INC
600 Highland Ave, Madison, WI 53792
Call: 608-263-6400

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

Targeted Genomic Analysis of Human Cancers
Targeted Genomic Analysis of Human Cancers
Enrollment Status: Recruiting
Publish Date: August 07, 2023
Intervention Type: Other
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin
Study Phase: Phase 3
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
Enrollment Status: Completed
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drug: 18F DCFPyL
Study Phase: Early Phase 1
Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drugs: Pembrolizumab, pTVG-HP Plasmid DNA Vaccine
Study Phase: Phase 1/Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer
Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer
Enrollment Status: Completed
Publish Date: June 18, 2021
Intervention Type: Biological
Study Phase: Phase 2
Validation of Imaging-Based Biomarkers of Treatment Response in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide
Validation of Imaging-Based Biomarkers of Treatment Response in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Other
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

96 Total Publications

Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.
Journal: European urology oncology
Published: November 04, 2024
View All 96 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Douglas G. Mcneel
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Douglas G. Mcneel
Oncology

University Of Wisconsin Medical Foundation Inc

600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-263-6400
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Douglas Mcneel is an Oncologist in Madison, Wisconsin. Dr. Mcneel is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Adult Soft Tissue Sarcoma, and Familial Prostate Cancer. Dr. Mcneel is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shahid Shekhani
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shahid Shekhani
Oncology | Hematology

Mercy Health System Corporation

N2950 State Rd, Suite 67, 
Lake Geneva, WI 
 (56.0 miles away)
262-245-0535
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Offers Telehealth

Shahid Shekhani is an Oncologist and a Hematologist in Lake Geneva, Wisconsin. Dr. Shekhani is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Lynch Syndrome, and Colorectal Cancer.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Joshua M. Lang
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Joshua M. Lang
Oncology

University Of Wisconsin Medical Foundation Inc

705 S University Ave, Suite 200, 
Beaver Dam, WI 
 (39.9 miles away)
920-887-9272
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joshua Lang is an Oncologist in Beaver Dam, Wisconsin. Dr. Lang is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Nasopharyngeal Carcinoma, Familial Prostate Cancer, Prostatectomy, and Nephrectomy. Dr. Lang is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Liu's expertise for a condition
ConditionClose
  • Elite
  • Prostate Cancer
    Dr. Liu is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Liu is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Liu is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Familial Prostate Cancer
    Dr. Liu is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Renal Cell Carcinoma (RCC)
    Dr. Liu is
    Distinguished
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Upper Tract Urothelial Carcinoma (UTUC)
    Dr. Liu is
    Distinguished
    . Learn about Upper Tract Urothelial Carcinoma (UTUC).
    See more Upper Tract Urothelial Carcinoma (UTUC) experts
  • WT1-Related Wilms Tumor Syndromes
    Dr. Liu is
    Distinguished
    . Learn about WT1-Related Wilms Tumor Syndromes.
    See more WT1-Related Wilms Tumor Syndromes experts
  • Advanced
  • Bone Tumor
    Dr. Liu is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Clear Cell Sarcoma
    Dr. Liu is
    Advanced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Liu is
    Advanced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Muscle Invasive Bladder Cancer
    Dr. Liu is
    Advanced
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Wilms Tumor
    Dr. Liu is
    Advanced
    . Learn about Wilms Tumor.
    See more Wilms Tumor experts
  • Experienced
  • Adrenal Cancer
    Dr. Liu is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Agranulocytosis
    Dr. Liu is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Bladder Cancer
    Dr. Liu is
    Experienced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Breast Cancer
    Dr. Liu is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Breast Cancer in Men
    Dr. Liu is
    Experienced
    . Learn about Breast Cancer in Men.
    See more Breast Cancer in Men experts
  • Choriocarcinoma
    Dr. Liu is
    Experienced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved